CTLA4 and cancer: The immune checkpoint mediators, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1) as well as programmed death-ligand 1 (PD-L1) have been validated to be effectively targeted and their antibodies have been approved by the Food and Drug Administration (FDA) for treating various types of cancer.